The tissue plasminogen activator (tPA) is the only Federal Drug Administration (FDA)-approved therapy for stroke treatment, but due to its various side effects and limited therapeutic window, it only benefits a small portion of stroke patients [7,8,9,10,11]. This evidence concerns the gene PLAT and stroke disorder.